➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Colorcon
Baxter
McKinsey
Express Scripts

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

LEVEMIR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for LEVEMIR

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Minneapolis Medical Research FoundationN/A
University of California, San FranciscoN/A
Albany College of Pharmacy and Health SciencesN/A

See all LEVEMIR clinical trials

Recent Litigation for LEVEMIR

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08

See all LEVEMIR litigation

Company Disclosures: US Patents for LEVEMIR

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 D.C.P. AF 1988 A/S (DK) 2008-02-10 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2015-05-12 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2013-09-17 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 001 2005-06-16   Get Started for $10 Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for LEVEMIR

These patents were identified by searching patent claims

Supplementary Protection Certificates for LEVEMIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004C/020 Belgium   Get Started for $10 PRODUCT NAME: INSULIN DETEMIR; AUTHORISATION NUMBER AND DATE: 56370 01 20040601
PA2004005 Lithuania   Get Started for $10 PRODUCT NAME: INSULIN DETEMIR
122004000035 Germany   Get Started for $10 PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601 FIRST REGISTRATION: LIECHTENSTEIN 5637001 5637101 5637201 20031110
300160 Netherlands   Get Started for $10 PRODUCT NAME: INSULINE DETEMIRUM; NATIONAL REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: CH 56370 20031110
PA2004005,C0792290 Lithuania   Get Started for $10 PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
C990042 Netherlands   Get Started for $10 PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
SPC015/2004 Ireland   Get Started for $10 SPC015/2004, 20060131, EXPIRES: 20181109
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.